TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02467361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
Study: NCT02097303

Intervention type: DRUG
Group type: OTHER
Intervention: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
Description: Radium Ra 223 dichloride - A targeted alpha particle-emitting pharmaceutical (a radiopharmaceutical drug) is a ready-to-use solution for intravenous injection containing the drug substance radium dichloride. The active moiety is the alpha particle emitting nuclide Ra-223, present as a divalent cation (223Ra2+) and Abiraterone Acetate - A CYP17 inhibitor, indicated in combination with prednisone for the treatment of subjects with metastatic castration-resistant prostate cancer. Administration of Abiraterone Acetate may result in mineralocorticoid-related adverse events (AEs), due to CYP17 inhibition. Therefore, Abiraterone Acetate is administered in combination with Prednisone to reduce the frequency of these AEs.
Study: NCT02463045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288
Study: NCT02049736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Study: NCT00965107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiopental
Description: Thiopental given as a bolus dose of 2,5 mg/kg.
Study: NCT04162379

Intervention type: DRUG
Group type: OTHER
Intervention: Oral tablet
Description: Patients will be allocated as single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mg for 3 successive dosing every 4th day then stop the drug totally).
Study: NCT00965107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol given as a bolus dose of 1 mg/kg.
Study: NCT04441177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PlayStation®VR training
Description: Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
Study: NCT04481698

Intervention type: OTHER
Intervention: Mesoglycan
Description: Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days

Intervention type: OTHER
Intervention: Mesoglycan
Description: Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days
Study: NCT03787342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double Flap Incision
Description: A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Periosteal Releasing Incision
Description: A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Lingual Flap
Description: A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periosteal releasing incision
Study: NCT02299947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haemocomplettan P

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00299494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: IV, 1.8 mg/m2, q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: IV, 1.8 mg/m2, q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: IV, 1.8 mg/m2, q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab 375 mg/m\^2 via IV infusion on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab 375 mg/m\^2 via IV infusion on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab 375 mg/m\^2 via IV infusion on Day 1
Study: NCT04921891

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular nerve block
Description: The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without nerve block
Description: The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
Study: NCT00383539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Split-virion influenza vaccine
Description: Vaccine Lot 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Split-virion influenza vaccine
Description: Vaccine Lot 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Split-virion influenza vaccine
Description: Vaccine Lot 3

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Split-virion influenza vaccine
Description: Control Vaccine
Study: NCT05520853

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT combined with PD-1 inhibitors and thoracic hyperthermia
Description: At least one lesion (primary or metastatic) was selected for SBRT treatment, and the radiotherapy dose of each lesion was 32Gy/4Fx. SBRT was combined with thoracic hyperthermia from the first fraction, and hyperthermia was performed 6 times, twice a week. PD-1 inhibitor was used on the second day after the completion of SBRT. The PD-1 inhibitor was administered at a dose of 200mg every time, every 3 weeks for 2 years (35 times total), or until the investigators deem that the patient need to discontinue the drug because of treatment-related toxicity or disease progression.
Study: NCT03969134

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63-KH
Description: The vaccine will be injected intramuscularly into the arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be injected intramuscularly into the arm.
Study: NCT00571181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop system
Description: Automatic delivery of propofol and remifentanil

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCI (Infusion Toolbox)
Description: TCI administration of propofol and remifentanil
Study: NCT02760095

Intervention type: DRUG
Intervention: 3 mg zinc sulfate supplement

Intervention type: DRUG
Intervention: 3 mg zinc sulfate supplement

Intervention type: DRUG
Intervention: 0.5 mg of 13C10-retinyl-acetate

Intervention type: DRUG
Intervention: 0.5 mg of 13C10-retinyl-acetate
Study: NCT01075295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention for the Prevention of Weight Gain
Description: The intervention consists of four steps:~* STEP 1 (Watchful Waiting): Measurement of body weight and Waist Circumference at the start (1 visit). Subjects that have a weight gain greater then or equal to 2% of their baseline weight will progress to Step 2~* STEP 2 (Self monitoring): Self-monitoring of daily weight, daily food intake \& physical activity (1 visit) Subjects that have a weight gain greater then or equal to 2% (from STEP 2) will progress to Step 3~* STEP 3 (Nutrition \& Exercise Counseling): Counseling for nutrition and physical activity (4 visits; 2 in-clinic, 2 telephone) Subjects that have a weight gain greater then or equal to 2% (from STEP 3) will progress to Step 4~* STEP 4 (Intensive): Intensive behavioral training geared towards reducing caloric intake (4 in-clinic visits)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as provided by individuals' existing healthcare providers
Study: NCT02964533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thunder-fire moxibustion therapy
Description: burn moxa stick and heat shenque acupoint

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: common moxa-stick moxibustion
Description: burn moxa stick and heat shenque acupoint
Study: NCT02440425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab: 200 mg, every (Q) 3 weeks, via intravenous (IV) infusion, until progression or toxicity (or up to 24 months). The first cycle will begin on day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: 80 mg/m\^2, Q week for 3 weeks, via IV infusion, until progression or toxicity (or complete response if at least 6 cycles, at the discretion of the investigator and participant). Cycle 1 will have an extra lead in week (4 weeks total) with Paclitaxel only on week 1.
Study: NCT02517762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study: NCT00214019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol
Description: salmeterol diskus 50 mcg twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol
Description: salmeterol diskus 50 mcg twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: placebo diskus, fluticasone MDI 88 mcg twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: placebo diskus, fluticasone MDI 88 mcg twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo diskus
Study: NCT03880136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Once daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Once daily dosing
Study: NCT03921099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.
Study: NCT02092623

Intervention type: DEVICE
Group type: OTHER
Intervention: Transvaginal posterior mesh
Description: A trocar-free fixation system with low-weight mesh
Study: NCT01567631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intrahepatic Glisson's approach
Description: Forty patients with liver disease were selected and divided into intrahepatic Glission's group as described in the detailed description.Total laparoscopic hepatectomy with intrahepatic Glisson's approach were performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle (containing arterial, portal, and bile duct branches ). A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler. The specimen was extracted through suprapubic incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classical hepatectomy
Description: Forty patients with liver disease were selected and divided into classical laparoscopic hepatectomy group as described in the detailed description.Total laparoscopic anatomical hepatectomy with classical procedure were performed.The initial step is to dissect hepatic portal and expose the liver artery, portal Vein branch and the bile duct. Then endoscopic stapler devices were used to cut the canal mentioned above. Final step is to divide the liver parenchyma along the following ischemic delineation.
Study: NCT03430947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.
Study: NCT01773083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Description: nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
Study: NCT05119127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon Vivity toric intra ocular lens
Description: implanting vivity toric IOL to asses rotational stability. IOL is already FDA approved for implantation at time of cataract surger. Intervention is to assess rotational stability and visual outcome.
Study: NCT03463629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized multidisciplinary diabetes team (SMDT) approach
Description: The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor.
Study: NCT03578653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Merging Yoga and Occupational Therapy for Parkinson disease
Description: The group occupational therapy portion focuses on lecture, group discussion, and activities to reduce fall risk. The yoga program is part of an ongoing community yoga program specifically designed for people with Parkinson disease.
Study: NCT03163927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Description: See arm description
Study: NCT01365481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
Study: NCT00472849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 30 mg/m\^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 30 mg/m\^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m\^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m\^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 IV on day 3, course 1 (on day 1, subsequent courses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 IV on day 3, course 1 (on day 1, subsequent courses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy
Study: NCT03364075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 30 mg for seven days, then increased to 60 mg for seven days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: 30 mg for seven days, then increased to 60 mg for seven days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: 40 mg for seven days, then increase to 60 mg for seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40 mg for seven days, then increase to 60 mg for seven days

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotype for SNPs associated to Serotonin and COMT
Description: DNA and RNA extraction from blood samples to identify genetic variants associated to pain pathways

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotype for SNPs associated to Serotonin and COMT
Description: DNA and RNA extraction from blood samples to identify genetic variants associated to pain pathways

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Treatment
Description: 1 capsule BID for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Treatment
Description: 1 capsule BID for two weeks
Study: NCT03463629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional model of care
Description: Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services
Study: NCT00955500

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain amino acids
Description: 30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
Study: NCT02915419

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: platelet rich plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: platelet rich plasma

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRF
Description: PLATELET RICH FIBRIN

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF
Description: PLATELET RICH FIBRIN
Study: NCT00955500

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: 30 grams of oral maltodextrin daily
Study: NCT01546051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-838
Description: BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
Study: NCT02261753

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Classical ketogenic diet
Description: A high fat low carbohydrate, low protein diet.
Study: NCT01546051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-838
Description: BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
Study: NCT01344772

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal fixation
Description: Two cannulated screws are placed under x-ray guidance